ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AS INDUCERS OF ADVERSE CUTANEOUS REACTIONS

U.M. STECKELINGS, M. ARTUC, T. WOLLSCHLÄGER, S. WIEHSTUTZ and B. M. HENZ
Department of Dermatology and Allergy, Charité, Humboldt University, Berlin, Germany

Since adverse effects due to angiotensin-converting enzyme (ACE) inhibitors frequently occur in cutaneous locations, this review summarizes the spectrum of expected and unexpected adverse effects of these drugs, possible associated mechanisms, and their basic functions for dermatologists. ACE inhibitors block the activity of the metalloproteinase ACE by binding to its active site, thus displacing angiotensin I and preventing its conversion to vasopressive angiotensin II. Furthermore, ACE degrades bradykinin, substance P, enkephalins and some of the reproductive peptide hormones. The overall incidence of adverse effects to ACE inhibitors is estimated at 28%, approximately half of which occurs in the skin. General reactions are first-dose hypotension, hyperkalaemia and renal failure. Cutaneous reactions comprise life-threatening angioedema, pruritus, bullous eruptions, urticaria, other generalized rashes, photosensitivity and hair loss. ACE inhibitors thus mimic a broad variety of skin diseases, why these drugs should be thought of when sudden, unexplainable skin eruptions are observed. **Key words:** ACE inhibitors; angiotensin; adverse events; angioedema; losartan.

(Accepted July 30, 2001.)


Ulrike M. Steckelings, Experimental Dermatology, Charité, Campus Virchow Klinikum, Augustenburger Platz 1, D-13344 Berlin, Germany. E-mail: steckelings@nexgo.de

Angiotensin-converting-enzyme (ACE) inhibitors are among the most commonly prescribed drugs, and are currently the standard medication in the treatment of hypertension and congestive heart failure (1, 2). They are the most frequently prescribed antihypertensive drugs because, apart from their high therapeutic efficiency, the incidence of severe adverse events from these agents is fairly low. Still, the overall incidence of adverse reactions (about 28%) is noteworthy, and, in particular, potentially life-threatening angioedema is feared (3). Adverse effects such as first-dose hypotension or hyperkalaemia can be explained by the physiology of ACE inhibition. The vast majority of adverse effects, however, is enigmatic and, although an explanation has been attempted in a number of studies, the nature of the underlying pathomechanisms remains speculative (4).

This review is aimed at familiarizing dermatologists with these drugs as well as their basic mechanisms and adverse effects in view of the potentially serious cutaneous reactions that may occur during their use. Initially, the known mechanisms of action of these drugs will be reviewed as a basis for an understanding of some of the most common adverse reactions to ACE inhibition. In the subsequent clinical part, the main focus will be on cutaneous adverse effects and their potential pathomechanisms. Finally, we present a novel explanation for ACE-inhibitor actions on skin.

**BASIC ASPECTS OF ACE-INHIBITOR FUNCTION**

ACE inhibitors block the activity of the metalloproteinase ACE by binding to its active site. They thereby neutralize the catalytic potency of the essential zinc ion and, coincidentally, displace angiotensin I (Ang I), its natural ligand and substrate (5).

Normally, Ang I is converted by ACE to angiotensin II (Ang II), the effective hormone of the renin-angiotensin system (RAS). Ang I, however, is not the only molecule which is cleaved by ACE. ACE acts in fact on a broad spectrum of substrates and is additionally responsible for the degradation of bradykinin, substance P, enkephalins and some of the reproductive peptide hormones (e.g. luteinizing hormone releasing factor (LHRH)). Thus, inhibition of ACE activity prevents not only the formation of Ang II, but also the breakdown of bradykinin, substance P and other peptides (Fig. 1) (5). The beneficial effect of ACE inhibitors on hypertension is based on several physiological mechanisms. A reduced supply of Ang II weakens its blood-pressure elevating actions, which are achieved by direct vasoconstriction, by an increase in body fluid volume through an enhanced release of mineralocorticoids, by an enhancement of vasopressin release, and by an activation of the sympathetic nervous system (1). In addition, bradykinin, if present in excess after ACE inhibition, has vasodilatory properties which contribute to the blood pressure lowering effect (1).

The beneficial effects of ACE inhibitors on heart failure are less well understood than those on hypertension. They most likely consist of a combination of limited left ventricular dilatation, lowered pre- and afterload, and reduced ventricular hypertrophy and fibrosis by opposing the trophic effects of Ang II on myocytes and fibroblasts (including collagen synthesis) (2). The latter effects may be enhanced by the antimitogenic properties of nitric oxide, which is released in response to bradykinin (6).

The acute effects of ACE inhibition (e.g. lowering of blood pressure) within the first 6h after drug intake coincide with a reduction of circulating Ang II. After that, Ang II plasma levels rise progressively back to baseline values, while the effects of ACE inhibition still last or – in the case of improvement of cardiac failure – even only begin to be measurable after several weeks of treatment (5). It is theorized that inhibition of the so-called tissue RAS mainly contributes to the chronic or long-lasting effects of ACE inhibitors (7). Tissue RASs are defined as the presence of angiotensinogen, renin and ACE in close proximity within one tissue or organ, enabling the local, tissue-specific synthesis of Ang II independent of plasma-born precursors (7). Such RASs have been described in various tissues, including rat skin (8) and, very recently, also in human skin (9).
ANGIOTENSIN GENES

\[
\begin{align*}
\text{Angiotensinogen} & \quad \downarrow & \quad \text{Renin} \\
& & \\
\text{Angiotensin I} & \quad \downarrow & \quad \text{Angiotensin converting enzyme (ACE)} \quad \rightarrow & \quad \text{inactive peptides} \\
& & \\
\text{Angiotensin II} & \quad \downarrow & \\
& & \\
\text{Angiotensin receptors (AT1 etc.)} & \\
\end{align*}
\]

Fig. 1. Schematic presentation of the main ACE-inhibitor actions in the renin-angiotensin system (RAS) and other enzymatic processes (LHRF = luteinizing hormone releasing factor).

GENERAL ADVERSE REACTIONS TO ACE INHIBITORS

Based on the mechanisms of action of ACE inhibitors, there are a number of predictable adverse reactions. One of these is first-dose hypotension. Patients at risk for an abrupt fall in blood pressure after a first ACE-inhibitor intake are more likely to have high plasma renin before treatment. This group involves patients pretreated with high doses of diuretics, those with treatment-resistant hypertension, and patients with renovascular disease (4). Since a fall in systolic blood pressure of 50 mmHg and more can cause syncope, stroke or myocardial infarction, close monitoring at the start of treatment with ACE inhibitors is recommended in high-risk patients in an inpatient setting. Another common early effect of ACE treatment is hyperkalaemia. A rise in plasma potassium after ACE-inhibitor intake is a result of decreased aldosterone secretion and thereby of decreased renal potassium excretion. ACE inhibitor-induced hyperkalaemia is of clinical relevance, however, only in patients taking additional, potassium-rais‐ing drugs, especially potassium-sparing diuretics or potassium supplements (4).

Renal failure is another potentially serious adverse effect of ACE treatment. Angiotensin II is thought to maintain glomerular filtration by constriction of renal efferent arterioles in case the blood pressure within renal vessels is markedly decreased and that this status is not compensated by the contralateral kidney. Such a situation can be caused by stenosis or thrombosis of the renal artery or arteries. Since ACE inhibition blocks the compensating mechanism, renal failure may be the result (4).

Next to these predictable undesirable events, non-predictable adverse reactions may occur as well. These include dry, irritating cough as the probable most common adverse effect of ACE inhibitors. This cough occurs in about 10% of patients (10), and twice as much in women than in men (11). The pathomechanism is not clear. The ACE inhibitor-induced accumulation of bradykinin or substance P has been suspected as causing the cough, but in diverse studies no indication supporting this theory can be found (12, 13). ACE inhibitor-induced cough is often of such severity that ACE-inhibitor treatment has to be stopped.

Other relatively common reactions include discomfort of the throat, voice changes or disturbances of taste, with an incidence of 5% to 10% (4). These are less disturbing, however, and therefore not of great clinical or scientific interest.

CUTANEOUS ADVERSE EFFECTS

Angioedema

Among the long list of possible cutaneous adverse effects (Table I), ACE inhibitor-induced angioedema – despite the low incidence of 0.1% to 0.2% – is much feared because of its potentially life-threatening upper airway obstruction in classical locations such as the tongue and oropharynx (14, 15). Other less frequent and less dangerous locations are the skin, especially close to joints, and the intestine, where symptoms include severe abdominal pain, diarrhoea and emesis (16).

Some features of ACE inhibitor-induced angioedema make its diagnosis particularly difficult. Thus, although in most cases the lesions occur within the first 4 weeks after onset of treatment, they may also appear as late as several months after the first treatment dose (14, 17). To add to the diagnostic difficulties, ACE inhibitor-induced angioedema may regress spontaneously, despite continuation of treatment (18). In the literature, there are several reports of patients who have

<table>
<thead>
<tr>
<th>Table I. Summary of general and cutaneous adverse effects of angiotensin-converting enzyme inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>General adverse effects</td>
</tr>
<tr>
<td>-------------------------</td>
</tr>
<tr>
<td>First-dose hypotension</td>
</tr>
<tr>
<td>Hyperkalaemia</td>
</tr>
<tr>
<td>Renal failure</td>
</tr>
<tr>
<td>Dry cough</td>
</tr>
<tr>
<td>Discomfort of the throat</td>
</tr>
<tr>
<td>Voice changes</td>
</tr>
<tr>
<td>Disturbances of taste</td>
</tr>
</tbody>
</table>

Acta Derm Venereol 81
suffered from multiple episodes of angioedema until the correct diagnosis was finally made (18, 19).

The pathomechanisms of ACE inhibitor-induced angioedema are still a matter of debate. It is speculated that the accumulation of vasoactive peptides (bradykinin, histamine, substance P, prostaglandins) as a result of ACE inhibition are involved (14). Several studies have reported on increased wealing in response to intradermal bradykinin injections in volunteers who had previously taken ACE inhibitors (20, 21). Whether this experimental setting is suitable as a model for angioedema is, however, questionable and, moreover, other studies have failed to demonstrate any changes in the weal reaction to bradykinin under concomitant ACE inhibition (14, 22, 23). The currently favoured theory is that bradykinin – and/or other vasoactive peptides – may be involved in angioedema, but that they induce symptoms only in combination with certain genetic predispositions. The incidence of angioedema is for example significantly higher in Blacks of African origin (about 4.5 times), compared to Caucasians (19, 24), and angioedema more often seems to have a severe, life-threatening course in this group. Racial and genetic differences in the kallikrein-kinin system may be responsible since Blacks of African origin have an increased sensitivity to bradykinin (25). Other predispositions that are not related to ethnic aspects seem to exist as well, since patients with a history of idiopathic angioedema are at higher risk of developing angioedema in response to ACE inhibitors (26, 27). A history of previous manipulation or trauma of upper airways also seems to predispose to ACE inhibitor-induced angioedema (28).

Although many data support a role for bradykinin and/or other vasoactive peptides in ACE inhibitor-induced angioedema, some cases seem to be governed by a different pathomechanism, since angioedema has also been described after administration of the angiotensin AT1-receptor antagonist losartan (29, 30). (For further comments and explanations, see the section “Adverse reactions to losartan” below.)

It is generally recommended that treatment regimens should be completely changed and ACE inhibitors avoided in patients with a history of ACE-inhibitor-induced angioedema (15, 19). Although some patients appear to be sensitive only to specific ACE inhibitors (31), the reoccurrence of angioedema after switching from one ACE inhibitor to another has also been reported (32, 33). Taking into account that every episode of angioedema bears the risk of ending fatally, the continuation of ACE-inhibitor therapy after ACE-inhibitor-induced angioedema should be an exception and restricted to patients in whom ACE inhibitors are necessary for survival.

**Urticaria**

Compared to angioedema, urticaria is an even rarer adverse effect of ACE-inhibitor treatment. In most cases, it occurs during the first month of drug intake. Captopril, which in contrast to the vast majority of other ACE inhibitors carries a sulphydryl group, seems to cause urticaria more often than the other drugs of this class (34).

**Bullous eruptions and acantholysis**

When one compiles case reports about cutaneous side effects of ACE inhibitors, it is striking that – apart from angioedema – the majority of eruptions include the formation of bullae.

The intracutaneous clef can be localized at different levels within or in-between the epidermis or dermis, and thereby mimic diverse “classical” bullous skin diseases such as pemphigus vulgaris (35), pemphigus vegetans (36), bullous pemphigoid (37), linear IgA bullous dermatosis (38), and lichen planus pemphigoides (39). In some cases of ACE inhibitor-induced bullous eruptions, circulating or tissue-bound autoantibodies characteristic of the respective idiopathic bullous skin disease have also been detected (35, 40), but numerous other case reports have failed to document such autoantibodies in this condition (35, 41).

*In vitro* experiments have revealed that ACE inhibitors can cause acantholysis via at least two different non-immunological mechanisms. On the one hand, drugs containing sulphydryl groups (thiols), such as the commonly used ACE inhibitor captopril, can evoke acantholysis by mechanisms interfering with the disulfide and thiol group balance (41, 42). On the other hand, enalapril, although lacking a sulphydryl group, turned out to be an even stronger acantholytic agent than captopril or other thiol drugs (43). The mechanisms by which enalapril induces acantholytic effects are not completely clarified, but seem to involve the inhibition of transglutaminase activity (42). Therefore, ACE inhibitors may cause bullous eruptions by direct interference with cell cohesion without any involvement of immunologic mechanisms.

**Other cutaneous adverse effects**

Further types of cutaneous undesirable effects by ACE inhibitors have been reported only as single case reports. These comprise pityriasis rosea-like (44), psoriasiform (45), maculopapular (46) and lichenoid eruptions (47), erythema multiforme (48), vasculitis (46), onycholysis (49), photosensitivity (50) and hair-loss (51). Pruritus has also been recorded and is of special importance because it often precedes angioedema (19, 52). Thus, patients should be advised to report pruritus immediately, since in that case an interruption of ACE-inhibitor therapy must be considered.

**ADVERSE REACTIONS TO LOSARTAN**

Losartan was the first drug marketed from a novel class of antihypertensives which function via a blockade of the angiotensin AT1 receptor. Since the AT1 receptor mediates all “classical” cardiovascular actions of angiotensin II, the pharmacological effects of losartan were expected to resemble those of ACE inhibitors; i.e. the receptor blockade was thought to have similar effects as a reduced supply of the effective ligand. Clinical studies have indeed shown that losartan is comparable to ACE inhibitors in terms of its efficacy in the treatment of hypertension as well as cardiac failure (53–55).

A comparison of desirable and adverse effects of AT1 blockers and ACE inhibitors is of special interest inasmuch as – according to current knowledge – AT1 antagonists exclusively interfere with the RAS, while ACE inhibitors additionally lead to the accumulation of various vasoactive peptides. Consequently, beneficial and undesirable effects that are identical after AT1 antagonist or ACE-inhibitor treatment, respectively, are most likely caused by inhibition of angiotensin II actions, while those that are seen only after ACE-inhibitor exposure probably involve the action of vasoactive peptides such as bradykinin (56).
The two adverse effects very typical of ACE inhibitors, namely cough and angioedema, are thought to involve bradykinin actions. Therefore, losartan was expected to be free of these adverse reactions. Nevertheless, several reports can be found about losartan-induced angioedema (29, 30), thus not supporting an exclusive involvement of bradykinin. Patients with a history of ACE-inhibitor-induced angioedema even seem to be at higher risk of developing the same adverse reactions under losartan treatment (57). Although the precise incidence of losartan-induced angioedema seems not to be clear as yet, the vast majority of investigators share the opinion that it is lower than with ACE inhibitors (58).

Dry cough has also been reported after losartan. Recent studies, however, reveal that the incidence of cough in losartan-treated patients is not significantly different, compared to patients receiving placebo, and it is significantly lower than in patients taking ACE inhibitors (59, 60). Taken together, the comparison of losartan versus ACE-inhibitor-induced adverse effects suggests that bradykinin is involved in cough induced by these drugs, but less significantly in angioedema. Further experiments and clinical observations are necessary to prove this hypothesis.

NEW ASPECTS OF THE PATHOMECHANISM OF ACE-INHIBITOR-INDUCED ADVERSE EFFECTS

Unlike the cutaneous undesirable effects of most other drugs, ACE-inhibitor-induced adverse reactions affecting the skin seem mostly to be based on non-immunological mechanisms. The feared complication of angioedema, for example, seems to be caused at least in some cases by an interference of ACE inhibition with local hormonal systems (bradykinin or other vasoactive peptides). The pathomechanisms of ACE-inhibitor-induced bullous eruptions seem in many cases to involve a direct influence of ACE inhibition on intercellular cohesion.

We were recently able to demonstrate the expression of a complete RAS in human skin, including the precursor of angiotensin II, angiotensinogen, the enzymes necessary for angiotensin II synthesis, renin and ACE, as well as angiotensin receptors of the AT1 and AT2 subtype (9, 61). These data suggest a local synthesis of angiotensin II in human skin and the existence of autocrine and paracrine systems. Thus, the expression of ACE makes it likely that ACE inhibitors directly interact with the cutaneous RAS, resulting in an inhibition of the local synthesis of angiotensin II. The physiological functions of angiotensin II in human skin and the consequences of a diminished synthesis are currently not known. We suggest, however, that putative alterations within the cutaneous RAS by ACE-inhibitor treatment should be considered when looking for the pathomechanisms of its adverse reactions. This holds especially true for the ACE-inhibitor-induced bullous eruptions, because angiotensin II is known to influence the expression of adhesion molecules and integrins (62, 63). Taken together, cutaneous adverse reactions to ACE inhibitors are common but far from being understood. Some involve immunological, the majority non-immunological mechanisms, one of which may be an interference with the local cutaneous renin-angiotensin system. Since they can mimic a broad variety of “classical” skin diseases, dermatologists should always consider them as the cause of sudden, inexplainable skin eruptions in patients taking ACE inhibitors, especially in the case of angioedema and bullous eruptions.

REFERENCES

21. Li Kam WC, Cooke ED, Turner P. A comparison of captopril and enalapril on skin responses to intradermal bradykinin and


